# US 2016/0354455 A1 · Chimeric nucleic acid molecules with non-aug translation initiation sequences and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354455 A1
- Document ID: US20160354455A1
- Status: Published application
- Kind: A1
- Application number: 15/180,852
- Filed: 2016-06-13
- Published: 2016-12-08
- Earliest claimed: 2014-03-17
- Assignees: Tapimmune, Inc.
- Applicants: TapImmune Inc.
- Inventors: Robert Z. Florkiewicz
- Web page: https://patentgrep.com/patent/US20160354455A1

## CPC

- C12N 15/85: for animal cells
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/001102: {Receptors, cell surface antigens or cell surface determinants}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/503: {basic FGF [bFGF]}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/82: Translation products from oncogenes
- C12N 15/67: General methods for enhancing the expression
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/645: {Dendrimers; Multiple antigen peptides}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C12N 2840/203: having an IRES
- C12N 2840/50: utilisation of non-ATG initiation codon
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure relates to nucleic acid vaccine compositions and methods for preventing or treating pathological conditions, such as cancer or infectious disease. Further, the disclosure provides methods for more efficient production of antigens via mRNA containing one or more non-conventional start codons to promote multiplex initiation of translation in eukaryotic cells.

## Claims

### Claim 1

A method of eliciting an immune response, comprising administering to a human subject a therapeutically effective amount of a chimeric nucleic acid molecule, wherein the chimeric nucleic acid molecule comprises a multiplex translation initiation (MTI) sequence comprising from two to about five translation initiation sites operatively linked in frame to a nucleic acid molecule encoding a fusion protein comprising from two to about ten human folate receptor-alpha (FRa) antigenic peptides, wherein at least one of the MTI translation initiation sites is a non-AUG translation initiation site and the MTI allows the production of more than one mole of fusion protein per mole of mRNA, thereby eliciting an immune response against one or more of the FRα antigenic peptides.

### Claim 2 (depends on 1)

The method of claim 1, wherein the MTI comprises one, two, three, or four non-AUG translation initiation sites.

### Claim 3 (depends on 2)

The method of claim 2, wherein one, two, three, or four of the non-AUG translation initiation sites are CUG translation initiation sites.

### Claim 4 (depends on 3)

The method of claim 3, wherein the MTI comprises an AUG translation initiation site downstream of the one, two, three, or four CUG translation initiation sites.

### Claim 5 (depends on 4)

The method of claim 4, wherein the MTI comprises one or two nuclear localization domains located upstream of the AUG translation initiation site and downstream of at least one CUG translation initiation site.

### Claim 6 (depends on 1)

The method of claim 1, wherein the MTI comprises a 5′-portion of a human FGF2 gene, wherein the 5′-portion of the human FGF2 gene contains an AUG translation initiation site and about 123 nucleotides to about 385 nucleotides upstream of the AUG translation initiation site that is in frame with the nucleic acid molecule encoding the fusion protein.

### Claim 7 (depends on 6)

The method of claim 6, wherein the MTI further comprises from about 15 nucleotides to about 45 nucleotides downstream of the AUG translation initiation site.

### Claim 8 (depends on 6)

The method of claim 6, wherein the 5′-portion of the human FGF2 gene encodes a polypeptide having at least 90% sequence identity to any one of the amino acid sequences set forth in SEQ ID NOS.:8-12, or encodes a polypeptide as set forth in any one of SEQ ID NOS.:8-12.

### Claim 9 (depends on 1)

The method of claim 1, wherein the MTI sequence has at least 90% sequence identity to a nucleotide sequence as set forth in any one of SEQ ID NOS.:1-6, 95, or 96.

### Claim 10 (depends on 1)

The method of claim 1, wherein the fusion protein comprises from two to about five different or same antigenic FRα peptides, or the fusion protein comprises five different antigenic FRα peptides.

### Claim 11 (depends on 1)

The method of claim 1, wherein one or more of the FRα antigenic peptides are an HLA Class I antigenic FRα peptide, an HLA Class II antigenic FRα peptide, an HLA Class II antigenic FRα peptide comprising an embedded HLA Class I antigenic FRα peptide, or any combination thereof.

### Claim 12 (depends on 1)

The method of claim 1, wherein one or more of the encoded FRα antigenic peptides of the fusion protein comprise from one to about ten junction amino acids, a spacer comprising from two to about 35 amino acids, a spacer comprising a (Gly4Ser)n wherein n is an integer from 1 to 5, a natural cleavage site comprising from one to about ten amino acids, a self-cleaving amino acid sequence, an intracellular trafficking sequence, one or more peptide tags, or any combination thereof.

### Claim 13 (depends on 1)

The method of claim 1, wherein the encoded fusion protein further comprises a self-cleaving amino acid amino-terminal to one or more of the encoded FRα antigenic peptides of the fusion protein, wherein the self-cleaving amino acid sequence comprises a 2A peptide from porcine teschovirus-1 (P2A), equine rhinitis A virus (E2A), Thosea asigna virus (T2A), or foot-and-mouth disease virus (F2A).

### Claim 14 (depends on 1)

The method of claim 1, wherein the encoded fusion protein further comprises a secretion signal amino acid sequence, a membrane localization amino acid sequence, a dendritic cell targeting amino acid sequence, or any combination thereof.

### Claim 15 (depends on 1)

The method of claim 1, wherein each encoded FRα antigenic peptide of the fusion protein has:
(a) an amino acid sequence of SEQ ID NOS.:69-73;
(b) at least 90% amino acid sequence identity to any one of SEQ ID NOS.:69-73;
(c) an amino acid sequence of SEQ ID NOS.:74-78;
(d) at least 90% amino acid sequence identity to any one of SEQ ID NOS.:74-78;
(e) an amino acid sequence of SEQ ID NOS.:79-93;
(f) at least 90% amino acid sequence identity to any one of SEQ ID NOS.:79-93;
(g) an amino acid sequence of SEQ ID NOS.:69-93;
(h) at least 90% amino acid sequence identity to any one of SEQ ID NOS.:69-93; or
(i) any one of (a)—(h) further comprising from one to about five spacer amino acids on the N-terminus, C-terminus or both of one or more of each FRα antigenic peptide of the fusion protein.

### Claim 16 (depends on 15)

The method of claim 15, wherein the encoded fusion protein encoding any one or more of SEQ ID NOS.:69-78 further comprises a secretion signal amino acid sequence, a membrane localization amino acid sequence, a dendritic cell targeting amino acid sequence, or any combination thereof.

### Claim 17 (depends on 15)

The method of claim 15, wherein the encoded fusion protein encoding any one or more of SEQ ID NOS.:69-78 further comprises:
(a) a VSVG signal amino acid sequence as encoded by the polynucleotide of SEQ ID NO.:43 that is operably linked in frame to and disposed between the MTI sequence and the nucleic acid molecule encoding the fusion protein;
(b) a VSVG trafficking amino acid sequence as encoded by the polynucleotide of SEQ ID NO.:47 or 48 that is operably linked in frame to the MTI sequence;
(c) a VSVG membrane localization amino acid sequence as encoded by nucleotides 457 to 516 of SEQ ID NO.:57 that is operably linked in frame to the MTI sequence;
(d) a VSVG trafficking amino acid sequence and membrane localization amino acid sequence as encoded by the polynucleotide of SEQ ID NO.:57 that is operably linked in frame to the MTI sequence; or
(e) any one of (a)—(d) further comprising a dendritic cell targeting amino acid sequence as encoded by the polynucleotide of SEQ ID NO.:45.

### Claim 18 (depends on 1)

The method of claim 1, wherein the encoded fusion protein comprises a polypeptide having at least 90% sequence identity with any one of the polypeptides set forth in SEQ ID NOS.:49, 67, or 68; or wherein the encoded fusion protein comprises a polypeptide having at least 90% sequence identity with any one of the polypeptides set forth in SEQ ID NOS.:53-55 or 59-61.

### Claim 19 (depends on 1)

The method of claim 1, wherein the chimeric nucleic acid molecule is:
(a) an mRNA molecule;
(b) a DNA molecule;
(c) a DNA molecule contained in a vector and operably linked to an expression control sequence.

### Claim 20 (depends on 19)

The method of claim 19, wherein the vector of subpart (c) comprises a plasmid vector or a viral vector.

### Claim 21 (depends on 20)

The method of claim 20, wherein the vector is a viral vector, the viral vector comprising a retroviral, lentiviral, adenoviral, or herpesvirus vector.

### Claim 22 (depends on 1)

The method of claim 1, wherein the chimeric nucleic acid molecule is formulated as a composition comprising a therapeutically acceptable carrier or excipient.

### Claim 23 (depends on 1)

The method of claim 1, comprising contacting the chimeric nucleic acid molecule with an immune cell ex vivo before administration, and administering to the human subject a population of immune cells containing the chimeric nucleic acid molecule.

### Claim 24 (depends on 1)

The method of claim 1, wherein the elicited immune response comprises a cellular immune response that treats a FRα-associated cancer.

### Claim 25 (depends on 1)

The method of claim 1, further comprising administering an effective amount of a antigenic peptide immunization composition comprising at least one FRα antigenic peptide.

### Claim 26 (depends on 25)

The method of claim 25, wherein the chimeric nucleic acid molecule encodes one or more of the same FRα antigenic peptides of the antigenic peptide composition.

### Claim 27 (depends on 26)

The method of claim 26, wherein:
(a) the chimeric nucleic acid molecule and the antigenic peptide immunization compositions are administered simultaneously;
(b) the chimeric nucleic acid molecule and the antigenic peptide immunization compositions are administered sequentially;
(b) the chimeric nucleic acid molecule is administered from 1 hour to 8 weeks after the antigenic peptide immunization composition;
(c) the antigenic peptide immunization composition is administered from 1 hour to 8 weeks after the chimeric nucleic acid molecule.

### Claim 28 (depends on 27)

The method of claim 27, further comprising one or more additional administrations of an effective amount of the antigenic peptide immunization composition and/or the chimeric nucleic acid molecule after the first administration of the antigenic peptide immunization composition and/or the chimeric nucleic acid molecule.

### Claim 29 (depends on 1)

The method of claim 1, further comprising administering an adjunctive therapy selected from the group consisting of surgery, chemotherapy, radiation therapy, antibody therapy, immunosuppressive therapy, and any combination thereof.

### Claim 30 (depends on 1)

The method of claim 1, further comprising administering an adjunctive therapy selected from the group consisting of cyclophosphamide, trastuzumab, anti-PD1, anti-PDL1, anti-CTLA4, and any combination thereof.
